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Resveratrol is a natural compound that affects
energy metabolism and mitochondrial function and
serves as a calorie restriction mimetic, at least in
animal models of obesity. Here, we treated 11
healthy, obesemen with placebo and 150mg/day re-
sveratrol (resVida) in a randomized double-blind
crossover study for 30 days. Resveratrol significantly
reduced sleeping and resting metabolic rate. In
muscle, resveratrol activated AMPK, increased
SIRT1 and PGC-1a protein levels, increased citrate
synthase activity without change in mitochondrial
content, and improved muscle mitochondrial respi-
ration on a fatty acid-derived substrate. Furthermore,
resveratrol elevated intramyocellular lipid levels and
decreased intrahepatic lipid content, circulating
glucose, triglycerides, alanine-aminotransferase,
and inflammation markers. Systolic blood pressure
dropped and HOMA index improved after resvera-
trol. In the postprandial state, adipose tissue lipolysis
and plasma fatty acid and glycerol decreased. In
conclusion, we demonstrate that 30 days of resvera-
trol supplementation induces metabolic changes in
obese humans, mimicking the effects of calorie
restriction.
INTRODUCTION
In our western society, the number of age-related chronic
diseases such as obesity, diabetes, and cancer increases
progressively (Crews, 2005). The only nonpharmacological inter-
vention known to date to alleviate these deleterious conditions is612 Cell Metabolism 14, 612–622, November 2, 2011 ª2011 Elseviercalorie restriction. Reduction of calorie intake to 30%–50%
below ad libitum levels or every-other-day feeding can delay
the onset of age-related diseases, improve stress resistance,
and decelerate functional decline (Barger et al., 2003; Goodrick
et al., 1990; McCay et al., 1989). Although short-term dietary
restriction has metabolic effects in humans such as lowering
metabolic rate (Heilbronn et al., 2006), improving insulin sensi-
tivity (Larson-Meyer et al., 2006; Lim et al., 2011), and reducing
cardiovascular risk factors (Lefevre et al., 2009), eating less for
the sake of creating a desirable metabolic profile is unlikely to
gain widespread compliance. As such, the focus has been on
the development of calorie restriction mimetics that evoke
some of the benefits of calorie restriction without an actual
reduction in calorie intake. In that respect, sirtuins are consid-
ered an important molecular target (Canto´ and Auwerx, 2009).
Indeed, it was suggested that the yeast Sir2 gene (Lin et al.,
2000) or its worm (Tissenbaum and Guarente, 2001) and fly (Ro-
gina and Helfand, 2004) orthologs are required for the effects
of calorie restriction, although the relevance of the role of Sir2/
SIRT1 as a strictu sensu longevity regulator is debated (Burnett
et al., 2011). What is clear, however, is that mammalian SIRT1
plays a context-dependent role in health span regulation, for
instance by mediating effects in metabolic stress situations,
such as high-fat-diet-induced obesity (Baur et al., 2006;
Lagouge et al., 2006; Pearson et al., 2008). As such, SIRT1 con-
fers protection against aging-associated metabolic diseases
such as glucose intolerance and cancer (Herranz et al., 2010;
Pearson et al., 2008; Rutanen et al., 2010). In light of the growing
number of patients suffering from metabolic diseases, com-
pounds that activate SIRT1 directly or indirectly might offer
protection against the onset of metabolic damage and promote
healthy aging.
To this end, Howitz and colleagues performed an in vitro
screen to identify small molecule activators of SIRT1 (Howitz
et al., 2003). Resveratrol, a natural polyphenolic compound pre-
sent in various dietary components such as mulberries, peanuts,Inc.
Table 1. Subjects’ Baseline Characteristics
Placebo Resveratrol P value
Age (years) 52.5 ± 2.1 52.5 ± 2.1 -
Body weight (kg) 100.1 ± 3.5 99.6 ± 3.7 0.50
BMI (kg/m2) 31.59 ± 0.74 31.45 ± 0.82 0.48
Fat percentage (%) 26.44 ± 0.53 26.44 ± 0.53 -
VO2max (ml.kg
1.min1) 24.96 ± 1.30 24.80 ± 1.00 0.83
Systolic blood pressure
(mmHg)
131 ± 3.1 132 ± 3.0 0.22
Diastolic blood pressure
(mmHg)
82 ± 2.5 83 ± 2.6 0.20
Glucose (mmol/l) 5.44 ± 0.10 5.44 ± 0.13 0.96
Insulin (mU/l) 16.37 ± 1.76 15.38 ± 2.05 0.67
Triglycerides (mmol/l) 1.86 ± 0.19 1.92 ± 0.21 0.80
Nonesterified fatty acids
(mmol/l)
357 ± 69 320 ± 31 0.56
Subject characteristics at the start of the intervention (day 0). Values are
given as means ± SEM (n = 11).
Table 2. Plasma Biochemistry
Placebo Resveratrol P value
Resveratrol (ng/ml) Not detectable 182.59 ± 30.33 -
Dihydroresveratrol (ng/ml) Not detectable 289.14 ± 93.57 -
Glucose (mmol/l) 5.28 ± 0.15 5.06 ± 0.13 0.05
Insulin (mU/l) 11.94 ± 1.11 10.31 ± 1.25 0.04
HOMA index 2.80 ± 0.20 2.43 ± 0.24 0.03
Triglycerides (mmol/l) 2.29 ± 0.23 2.16 ± 0.21 0.03
Nonesterified fatty acids
(mmol/l)
572 ± 77 621 ± 38 0.59
Leptin (ng/ml) 14.28 ± 1.98 12.91 ± 1.84 0.04
Adiponectin (mg/ml) 6.47 ± 0.55 6.45 ± 0.56 0.95
CRP (ng/ml) 1.52 ± 0.35 1.33 ± 0.31 0.11
IL-1b (pg/ml) 1.33 ± 0.27 0.94 ± 0.15 0.20
IL-6 (pg/ml) 3.13 ± 0.67 2.42 ± 0.38 0.09
IL-8 (pg/ml) 4.94 ± 0.59 4.28 ± 0.25 0.19
TNF-a (pg/ml) 16.15 ± 2.27 15.14 ± 2.03 0.04
Leukocytes (109/l) 7.03 ± 0.44 6.48 ± 0.39 0.03
ALAT (U/l) 31.91 ± 2.21 28.09 ± 1.54 0.02
Plasma values after 30 days of resveratrol or placebo supplementation.
Values are given as means ± SEM (n = 11). See also Table S1.
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Metabolic Effects of Resveratrol in Humansgrapes, and red wine, was identified as the most potent activator
of SIRT1 (Howitz et al., 2003). Recently, however, it was shown
that resveratrol may not activate SIRT1 directly (Beher et al.,
2009; Pacholec et al., 2010), but rather exerts its effects on
SIRT1 through activation of AMPK (Baur et al., 2006; Canto´
et al., 2009, 2010; Feige et al., 2008; Hawley et al., 2010; Um
et al., 2010), although additional direct SIRT1 activation is not
completely excluded (Dai et al., 2010). Regardless of the mode
of activation, resveratrol treatment in mice fed a high-calorie
diet consistently improved various health parameters, including
glucose homeostasis, endurance, and survival (Baur et al.,
2006; Lagouge et al., 2006; Pearson et al., 2008; Sun et al.,
2007), and has therefore been suggested to act as a calorie
restriction mimetic. However, so far no human studies have
been reported that have systematically examined the metabolic
effects of resveratrol in vivo.
Here, we gave obese but otherwise healthy subjects a dietary
supplement containing 99%pure trans-resveratrol (resVida) over
30 days and examined whole-body energy expenditure,
substrate utilization, ectopic lipid storage, mitochondrial func-
tion, and lipolysis in adipose tissue and skeletal muscle using
a combination of in vivo and ex vivo measurements. Our data
show that like calorie restriction, resveratrol supplementation
lowers energy expenditure and improves metabolic profile as
well as general health parameters.
RESULTS
Study Design and Plasma Biochemistry
Eleven obese but otherwise healthy male volunteers without a
family history of diabetes or any other endocrine disorder partic-
ipated in this study. Baseline characteristics of the subjects are
included in Table 1. Subjects participated in two experimental
trials: (1) a placebo and (2) a resveratrol (150 mg/day [99%]
resVida) (provided by DSM Nutritional Products, Ltd.) condition
in a randomized, double-blind, crossover design with a 4 week
wash-out period. Subjects were instructed to take the firstCell Msupplement on the day after the baseline measurements
(day 1) and the last supplement in the evening on day 29.
To ensure that the subjects adhered to the study protocol and
to confirm systemic conversion of resveratrol to dihydroresvera-
trol (DHR), total (sum of conjugated and unconjugated resvera-
trol) and free plasma levels of both compounds were analyzed
each week during the 30 day period of resveratrol or placebo
supplementation. Whereas no resveratrol or DHR could be de-
tected in the placebo group, both compounds were present in
plasma of resveratrol-supplemented subjects (Table 2, levels
at day 30 are shown and are representative for the whole inter-
vention period). Whereas measurement of plasma resveratrol
demonstrated compliance to the study protocol and indicated
that the compound was well absorbed, measurement of
DHR confirmed that resveratrol was efficiently metabolized,
especially as the plasma levels of DHR exceeded those of
resveratrol after an overnight fast. No detectable levels of free
resveratrol and free DHR were observed in the plasma in both
the resveratrol and placebo periods, also confirming efficient
metabolism. It is important to note that although the dosage of
150 mg of resveratrol per day is around 133- to 266-fold lower
compared to the high doses of 200–400 mg/kg/day used to
supplement mice (Baur et al., 2006; Lagouge et al., 2006),
plasma resveratrol levels in our human intervention (231 ng/ml
on average during the 30 days) were even higher than those
obtained in mice (10–120 ng/ml) (Lagouge et al., 2006). These
differences may be due to different metabolic rates of resveratrol
between humans and mice and therefore suggest that resvera-
trol may exert its effects at different concentration ranges in
different mammals.
To ensure that resveratrol supplementation did not cause
adverse effects, we screened plasma and blood of the subjects
for several general health parameters. Clinical chemistry,etabolism 14, 612–622, November 2, 2011 ª2011 Elsevier Inc. 613
Table 3. Clinical Improvement after Resveratrol
Placebo Resveratrol P value
24 hr respiratory quotient 0.89 ± 0.007 0.91 ± 0.006 0.09
Respiratory quotient daytime 0.89 ± 0.004 0.91 ± 0.003 0.001
Respiratory quotient nighttime 0.87 ± 0.007 0.88 ± 0.009 0.18
24 hr energy expenditure
(MJ/day)
11.86 ± 0.29 11.91 ± 0.29 0.64
Sleeping metabolic rate
first night (MJ/day)
8.09 ± 0.24 7.75 ± 0.23 0.007
Sleeping metabolic rate
second night (MJ/day)
8.06 ± 0.22 7.90 ± 0.18 0.06
Diet-induced thermogenesis
(MJ/day)
1.02 ± 0.13 1.14 ± 0.17 0.33
Physical activity index 1.49 ± 0.02 1.50 ± 0.01 0.37
Systolic blood pressure
(mmHg)
130.5 ± 2.7 124.7 ± 3.1 0.006
Diastolic blood pressure
(mmHg)
81.6 ± 2.8 80.0 ± 2.9 0.18
Mean arterial pressure
(mmHg)
97.9 ± 2.7 94.9 ± 2.9 0.02
Energy metabolism (n = 10), and blood pressure (n = 11) after 30 days of
resveratrol or placebo supplementation. Values are given as means ±
SEM. See also Table S2.
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Metabolic Effects of Resveratrol in Humanshematology, and coagulation analysis revealed no adverse
effects after 30 days of resveratrol (see Table S1 available on-
line). Plasma ALAT concentrations were significantly lower after
resveratrol compared to placebo (Table 2). Also, leptin levels and
leukocytes in the plasma were significantly lower in resveratrol-
treated subjects (Table 2). In line with the reduced leukocyte
count, resveratrol also lowered some markers of systemic
inflammation, including IL-6 and TNF-a (Table 2). Electrocardio-
grams (ECGs) were inconspicuous and did not raise clinical
concern in any subject. No clinical adverse events were reported
during the resveratrol supplementation.
Next, we assessed whether resveratrol also exerted positive
effects on plasma markers that predict the metabolic risk for
development of diabetes and shorter life span. After 30 days of
resveratrol, plasma glucose and insulin concentrations were
lower compared to placebo (Table 2), resulting in a lower
HOMA index, indicative of improved insulin sensitivity (Table 2).
Plasma triglyceride concentrations were significantly lower after
resveratrol compared to placebo. No differences were observed
in plasma nonesterified fatty acids (NEFAs) (Table 2).
Clinical Improvement after Resveratrol
Supplementation
As calorie restriction was described to associate with reduced
absolute and body weight-adjusted 24 hr energy expenditure
and sleeping energy expenditure (Heilbronn et al., 2006), we
sought to investigate whether resveratrol treatment induced
similar metabolic adaptations. Indeed, resveratrol supplementa-
tion for a period of 30 days had a profound effect on resting
energy expenditure (Table 3). Subjects had a significantly lower
sleeping metabolic rate (SMR) compared to placebo, even
though 24 hr energy expenditure was similar between resveratrol
and placebo (Table 3). Although calorie restriction causes meta-614 Cell Metabolism 14, 612–622, November 2, 2011 ª2011 Elsevierbolic adaptations also partly through weight loss, we found no
effect on body mass (99.9 ± 3.9 kg versus 99.6 ± 2.5 kg, in res-
veratrol versus placebo, p = 0.43). Respiratory quotient (RQ)
values over 24 hr tended to be higher after resveratrol supple-
mentation, which was largely accounted for by higher RQ values
during the daytime (Table 3, the complete time course for the RQ
and the energy expenditure over 24 hr is shown in Table S2). The
higher RQ in the resveratrol group is especially apparent after
periods of feeding and suggests improved metabolic flexibility,
i.e., the ability to switch between energy substrates. No differ-
ences were observed in diet-induced thermogenesis or physical
activity index (Table 3).
Next, we investigated whether resveratrol also exerted favor-
able effects on other general health parameters. As long-term
calorie restriction in humans (Lefevre et al., 2009; Meyer et al.,
2006) and resveratrol treatment in mice (Lagouge et al., 2006)
was shown to ameliorate cardiac function, we examinedwhether
resveratrol also exerts beneficial effects on blood pressure. Res-
veratrol significantly lowered systolic blood pressure by
5 mmHg, while resveratrol had no effect on diastolic blood
pressure (Table 3). Mean arterial pressure was significantly lower
after resveratrol supplementation (Table 3).
Postprandial Substrate Utilization and Tissue Lipolysis
Mounting evidence implicates SIRT1 as a switch in substrate
utilization, for instance from glucose to fatty acid oxidation under
low-nutrient conditions (Canto´ and Auwerx, 2009; Feige et al.,
2008). Therefore, we next investigated whether resveratrol is
able to increase fat oxidation in adipose tissue and skeletal
muscle after a mixed meal by stimulating tissue lipolysis. The
peak glucose and insulin responses after consuming a liquid
test meal were reached after 30 min for placebo and after
60 min for resveratrol (Figures 1A and 1B). There was a tendency
for NEFAs (area under the curve [AUC] 4–6 hr, p = 0.13) and free
glycerol (AUC 4–6 hr, p = 0.06) to be lower in the late postprandial
phase after resveratrol (Figures 1C and 1D). Resveratrol did not
alter postprandial triglyceride and lactate responses (data not
shown). Using the microdialysis technique, ethanol out/in ratios
were determined to measure blood flow. At baseline, ethanol
out/in ratios were not different after resveratrol supplementation
compared to placebo, both in adipose tissue (0.81 ± 0.02 versus
0.81 ± 0.02, respectively) and in skeletal muscle (0.46 ± 0.02
versus 0.49 ± 0.02, respectively). Furthermore, resveratrol did
not affect postprandial adipose tissue and skeletal muscle blood
flow (data not shown). The interstitial glycerol concentration in
adipose tissue was slightly lower in the resveratrol condition in
the mid and late postprandial phases, although it did not reach
statistical significance (AUC 2–4 hr, p = 0.14; AUC 4–6 hr, p =
0.13) (Figure 1E). Therewere no differences in interstitial glucose,
pyruvate, and lactate responses in adipose tissue between
placebo and resveratrol (data not shown). For skeletal muscle,
there were no differences in interstitial glucose, pyruvate,
lactate, and glycerol concentrations (glycerol data shown Fig-
ure 1F). Interestingly, energy expenditure in the postprandial
period was significantly lower after resveratrol supplementation
(AUC, p = 0.02) (Figure 1G). During the late postprandial phase
(4–6 hr), RQ tended to be higher (AUC 4–6 hr, p = 0.07) (Fig-
ure 1H), and fat oxidation was decreased in the resveratrol
condition (AUC 4–6 hr, p = 0.007) (Figure 1I).Inc.
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Figure 1. Resveratrol Decreases Postprandial Energy Expenditure and Lowers Adipose Tissue Lipolysis
(A–I) Data are obtained on whole-body (A–D) by microdialysis (E and F) and indirect calorimetry (G–I). Plasma metabolites during the postprandial microdialysis
test after 30 days of placebo or resveratrol supplementation are shown as follows: glucose response (A), insulin response (B), NEFA response (C), free glycerol
response (D). Interstitial glycerol responses in adipose tissue (E) and skeletal muscle (F) during the postprandial microdialysis test are shown. Indirect calorimetry
results during the postprandial microdialysis test are shown as follows: energy expenditure (G), respiratory quotient (H), fat oxidation (I). Values are given as
means ± SEM (n = 10).
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Metabolic Effects of Resveratrol in HumansMolecular Mechanism of Resveratrol Treatment
To clarify the mechanism of action of resveratrol, we performed
microarray analysis on vastus lateralis muscle biopsies. We
found 469 genes to be differentially expressed between placebo
and resveratrol supplementation, 219 of which were increased
and 250 decreased (Figure 2A). We performed gene set enrich-
ment analysis (GSEA) to define the pathways that were affected
by resveratrol and to compare the expression profile with
previous studies in mouse (Lagouge et al., 2006). Several gene
sets related to mitochondrial oxidative phosphorylation were up-
regulated, whereas pathways linked to inflammation were down-
regulated upon resveratrol supplementation (Table S3). Indeed,
when analyzing expression of the individual genes in the oxida-
tive phosphorylation-related gene sets, we observed a marked
increase (Figure 2B, left panel), while for cytokine signaling, there
was a clear decrease (Figure 2B, right panel). Importantly, these
effects are highly similar to the effects observed in mice treated
with resveratrol (Figure 2C), even though the effects in the latter
are more pronounced, probably due to longer treatment time
and their identical genetic and environmental background.Cell MSince resveratrol was shown to activate AMPK, we measured
levels of phosphorylated AMPK on the Thr172 residue of the
a subunit—a marker for its activation. Indeed, increased AMPK
phosphorylation was observed in muscle biopsies of the resver-
atrol-treated subjects (Figures 3A and S1A).
Mitochondrial Metabolism
Our microarray data clearly suggested strong involvement of
mitochondrial function in the beneficial effects of resveratrol.
We hence performed more detailed analyses of mitochondrial
function. Mitochondrial DNA (mtDNA) copy number in the res-
veratrol condition was similar to the values obtained after
placebo (994.8 ± 101.4 versus 1074.7 ± 109.9 AU in resveratrol
versus placebo, p = 0.20). Also, neither the protein content of
the individual structural components of the individual OXPHOS
complexes nor the mean of all these complexes revealed
differences in mitochondrial density in resveratrol compared to
placebo supplementation (Figures 3B and S1B). On the other
hand, protein content of the AMPK downstream effector SIRT1
(Canto´ et al., 2009) as well as the mitochondrial master regulatoretabolism 14, 612–622, November 2, 2011 ª2011 Elsevier Inc. 615
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Figure 2. Resveratrol Increases Oxidative Phosphorylation Gene Expression in Man and Mice
(A) One-way hierarchical clustering of genes significantly changed in a microarray of muscle vastus lateralis of subjects receiving resveratrol (RSV) or placebo. In
muscle, 469 genes were differentially expressed between placebo and RSV (n = 10, p < 0.05).
(B) Gene set enrichment analysis (GSEA) of muscle microarray revealed that gene sets related to mitochondrial oxidative phosphorylation were significantly
increased (left panel) and cytokine signaling decreased (right panel) following resveratrol supplementation in humans.
(C) Previously published microarray data of mice treated with 400 mpkd RSV (Lagouge et al., 2006) were reanalyzed by GSEA, showing, like the human data,
a marked enrichment of oxidative phosphorylation genes. See also Table S3.
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Metabolic Effects of Resveratrol in HumansPGC-1a were significantly increased after 30 days of resveratrol
(Figures 3C and S1C), as was citrate synthase activity (Fig-
ure 3D), a common marker for mitochondrial activity.
Mitochondrial function can also be assessed in vivo by
measurement of phosphocreatine (PCr) recovery rate after exer-
cise (Schrauwen-Hinderling et al., 2007). To this end, single leg
extension exercise was performed for 5 min with a weight corre-
sponding to 60% of maximal capacity, which was determined
with an incremental maximal test on the same ergometer on a
different day. Low- to medium-intensity exercise was chosen
to prevent acidification of the muscle, which is known to affect
PCr recovery. Spectra were acquired 2 min before exercise,
during the 5 min of knee extension exercise, and during the
subsequent 5 min of recovery (rest). As targeted, PCr levels
decreased during the knee-extension exercise until a steady
state was reached. However, mean PCr recovery half time
(PCr-t1/2) was unchanged by resveratrol compared to placebo
(Figure 3E).
To functionally characterize mitochondrial oxidative phos-
phorylation in more detail, we measured mitochondrial respira-
tion using different substrate combinations. State 2 respiration
(i.e., respiration in the presence of exogenous substrates alone)616 Cell Metabolism 14, 612–622, November 2, 2011 ª2011 Elsevierwas not different between resveratrol versus placebo on any
of the substrate combinations studied (data not shown). ADP-
stimulated (state 3) respiration on a lipid substrate (malate +
octanoyl-carnitine, MO) tended to be higher after resveratrol
supplementation (p = 0.075, Figure 3F). State 3 respiration
upon the complex I-linked substrates malate + glutamate (MG)
was unaffected (Figure 3G). Respiration upon parallel electron
input to both complex I and II was10%higher upon resveratrol.
Thus, state 3 respiration upon malate + octanoyl-carnitine +
glutamate (MOG) was significantly higher in subjects receiving
resveratrol (Figure 3H). Similar differences were observed for
state 3 respiration upon malate + octanoyl-carnitine +
glutamate + succinate (MOGS) (Figure 3H), but not in the
absence of octanoyl-carnitine (malate + glutamate + succinate,
MGS) (Figure 3H). Maximal FCCP-induced uncoupled respira-
tion, measured in the presence of octanoyl-carnitine, reflecting
the maximal capacity of the electron transport chain, was also
higher after 30 days of resveratrol (Figure 3I). State 4o respiration
(reflecting mitochondrial proton leak) was similar between re-
sveratrol and placebo condition (Figure 3J). Similar results
were obtained if respiration rates were not corrected for mtDNA
copy number.Inc.
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Figure 3. Resveratrol Increases AMPK Activity, Mitochondrial Efficiency, and Respiration on Fatty Acid Substrates
(A) After 30 days of resveratrol or placebo, a muscle biopsy was obtained from the vastus lateralis muscle. Of total protein extracts from the vastus lateralis
muscle, 50 mg of protein was used to check the expression levels of several proteins by western blotting. Shown in (A) is the level of phosphorylation of residue
Thr172 of the AMPKa subunit (top panel), indicative of AMPK activity, obtained by western blotting in a total of nine subjects per group (representative subset is
shown). Total level of the AMPKa protein is shown in the bottom panel. The ratio of resveratrol to placebo is shown on the right of (A). Relative quantification of the
ratio of pAMPK to AMPK is shown in Figure S1A.
(B) The protein content of the individual complexes of the electron transport chain is quantified by western blotting in vastus lateralis muscle of 11 subjects per
group. An antibody cocktail that detects all five complexes is used, and the values are given as means ± SEM for the individual complexes as well as for the
average expression of all the complexes. A representative western blot is included in Figure S1B.
(C) SIRT1 and PGC-1a protein levels in vastus lateralis muscle by western blotting (n = 8 for SIRT1 and n = 11 for PGC-1a; a representative subset is shown). The
relative expression of both proteins is corrected for the loading control, tubulin for SIRT1 and actin for PGC-1a. The ratio of resveratrol to placebo is shown on the
right of (C). The relative quantification of the western blots is shown in Figure S1C.
(D) Citrate synthase activity was significantly increased in vastus lateralis muscle of resveratrol (RSV)-treated subjects (n = 11). Values are given as means ± SEM,
*p < 0.05.
(E) In vivo mitochondrial function expressed as PCr half-time (n = 11). Values are given as means ± SEM.
(F–J) Evaluation of ex vivo mitochondrial function in vastus lateralis muscle: ADP-stimulated respiration (state 3) upon a lipid substrate (F); state 3 respiration
fueled by complex I-linked substrates (G); state 3 respiration upon parallel electron input into complex I and II, *p < 0.05 (H); maximally uncoupled respiration upon
FCCP, *p < 0.05 (I); mitochondrial respiration uncoupled from ATP synthesis (state 4o) (J). Values are given as means ± SEM (n = 10). M, malate; O, octanoyl-
carnitine; G, glutamate; S, succinate.
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Metabolic Effects of Resveratrol in HumansLipid Accumulation in Liver and Skeletal Muscle
Since our data show that resveratrol clearly induced a shift in
mitochondrial substrate selection, we tested whether this was
also reflected in liver and skeletal muscle lipid accumulation. In-
trahepatic lipid (IHL) content was lower after 30 days of resvera-
trol supplementation in comparison to placebo (Figure 4A). This
was paralleled by lower plasma ALAT values, as mentioned
before, both indicating improved liver function. The mean intra-
myocellular lipid (IMCL) area fraction was 2-fold higher in the
resveratrol group (Figure 4B). The increase in lipid accumulation
wasmore pronounced in fibers identified as slow, oxidative (type
1) fibers than in type 2 muscle fibers (Figure 4B).
DISCUSSION
Resveratrol, which was discovered in a small-molecule screen
as a potent SIRT1 activator (Howitz et al., 2003), has been exten-
sively studied in animal and cellular studies with promising
results (Baur et al., 2006; Lagouge et al., 2006). Here, we showCell Mthat resveratrol supplementation in humans exerted favorable
metabolic adaptations that in many aspects mimic the effects
of calorie restriction and/or endurance training (Civitarese
et al., 2007; Heilbronn et al., 2006; Larson-Meyer et al., 2006,
2008; Lefevre et al., 2009). These metabolic adaptations include
a reduction in SMR, blood pressure, and hepatic lipid content, an
improvement in skeletal muscle intrinsic mitochondrial function
and several plasma markers of general health, an increase
in IMCL content, as well as an increase in skeletal muscle
PGC-1a protein content. These data extend findings, which so
far have been observed only in cell and rodent models, to the
human situation, showing that resveratrol has promising benefi-
cial metabolic effects, and suggest that resveratrol has the
potential to improvemetabolic health in subjects at risk for devel-
oping the metabolic syndrome.
Resveratrol exerts significant effects on energy metabolism.
SMR was significantly lower following 30 days of resveratrol
supplementation, without changing 24 hr energy expenditure.
It should be noted that SMR is the component of human energyetabolism 14, 612–622, November 2, 2011 ª2011 Elsevier Inc. 617
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Figure 4. Resveratrol Decreases IHL Content but
Increases Intramyocellular Lipid Content
(A) Ectopic lipid deposition after 30 days of placebo or
resveratrol supplementation. Typical lipid regions of
hepatic 1H-MR spectra from a subject receiving placebo
(left) and resveratrol (right) at 3T, scaled to the water
resonance (reference), are shown in (A). The CH2 peak is
used for quantification; the area under the curve is
proportional to the lipid content in the liver. Quantification
revealed that IHL content was reduced by resveratrol (n =
9), *p < 0.05.
(B) Images of representative cross-section of the vastus
lateralis muscle from a subject receiving placebo (top) and
resveratrol (bottom). Sections are stained for intra-
myocellular lipids with oil red O staining (in red), muscle
laminin (in blue), and type 1 muscle fibers (in green) (4003
magnification). IMCL content significantly increased by
resveratrol treatment in muscle fibers, which was mostly
accounted for by an increased lipid storage in type 1
muscle fibers (n = 10), *p < 0.05. Values are given as
means ± SEM.
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Metabolic Effects of Resveratrol in Humansmetabolism that is most sensitive to metabolic changes—as it is
not affected by physical activity—and small differences in
sleeping energy expenditure can be detected with high accu-
racy. In line with this, we observed that basal and postprandial
energy expenditure was also lower after 30 days of resveratrol
supplementation. The 2%–4% reduction in energy expenditure
upon resveratrol treatment is consistent with the effects
observed after calorie restriction (6% reduction) (Heilbronn
et al., 2006; Martin et al., 2007).
It is important to note that basal and postprandial energy
expenditure were reduced rather than increased by resveratrol
in our human study, as was true for mice (Lagouge et al.,
2006). Although our energy expenditure data are opposite to
the effects seen in mice, a lowering of resting metabolic rate
and SMR is likely a reflection of improved metabolic efficiency
and completely in line with the endurance training or calorie
restriction-like effects of resveratrol (Heilbronn et al., 2006;
Martin et al., 2007). Although the dose used in our human study
was 200-fold lower than doses used in the mouse studies, we
reached similar plasma resveratrol concentrations. We cannot
exclude, however, that metabolism of resveratrol is different
between mouse and man and, possibly more importantly, that
timing of treatment (30 days in our study versus 4–6 months in
mice [Baur et al., 2006; Lagouge et al., 2006]) significantly
impacts physiological outcome.
Prolonged calorie restriction (during 6 months) has also been
suggested to increase the expression of genes encoding
proteins involved in mitochondrial biogenesis and function
(Civitarese et al., 2007). Similarly, our microarray data indicate
increased mitochondrial gene expression in muscle following
resveratrol supplementation. In fact, we showed that this induc-
tion is likely to be mediated by AMPK—which is activated by re-
sveratrol—and resulted in increased SIRT1 and PGC-1a protein
content, accompanied by increased citrate synthase activity,
suggesting that mitochondrial activity was effectively improved.618 Cell Metabolism 14, 612–622, November 2, 2011 ª2011 ElsevierMoreover, detailed mitochondrial characterization revealed that
resveratrol had beneficial effects on mitochondrial respiration
when octanoyl-carnitine was used as a substrate, but not when
only glutamate was used. These data suggest that resveratrol
specifically improves muscle fat oxidative mitochondrial
capacity. Interestingly, we have recently found comparable
effects in PGC-1a-overexpressing mice, showing an improved
intrinsic mitochondrial function (i.e., respiration per mitochon-
drion), but only when fatty acids are used as a substrate (Hoeks
et al., 2011). The fact thatmtDNA copy number, OXPHOSprotein
content, and PCr recovery were not changed in resveratrol-
treated subjects suggests that 30 days resveratrol treatment
mostly affects mitochondrial efficiency, not abundance. It is
possible that more long-term treatment would cause these
parameters to change as well.
Interestingly, IMCL content was markedly increased after
30 days of resveratrol supplementation. Together with the
improvement in muscle fat oxidative capacity and the other
beneficial metabolic adaptations like lowering of circulating
triglyceride and glucose levels, the present data hint toward
endurance training-like effects of resveratrol (Dube´ et al., 2008;
Meex et al., 2010). Consistent with data in rats, where resveratrol
has been shown to reduce hepatic lipid synthesis (Ahn et al.,
2008; Arichi et al., 1982), we observed reduced IHL content.
Recent data suggest that endurance training is also able to lower
IHL content (Kantartzis et al., 2009), as was calorie restriction,
although this effect was mainly attributed to a reduction in
body weight (Larson-Meyer et al., 2006; Lim et al., 2011). Taken
together with the reduced plasma triglycerides and increased
muscle fatty acid oxidation, we hypothesize that fat is liberated
from peripheral depots to be metabolized by the muscle. Again,
here our data suggest that resveratrol mimics the effect of calorie
restriction and endurance training. Also, we have investigated
postprandial metabolism, but found only a reduction in total
energy expenditure that was reflected by a lower fat oxidationInc.
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Metabolic Effects of Resveratrol in Humansduring the late postprandial phase—a change that is reminiscent
of the role of SIRT1 in regulating the efficient switch in energy
substrate utilization (Canto´ et al., 2009, 2010). Although post-
prandial lipolysis tended down, this does not refute our hypoth-
esis of increased fat mobilization, but rather confirms the idea of
improved metabolic flexibility.
A striking finding in our study was the resveratrol-induced
reduction of systolic blood pressure by 5 mmHg. In rodents,
resveratrol is also vasoactive and has been shown to cause
vasodilatation and to improve aortic endothelial function in dia-
betic mice (Wang et al., 2011), to reduce heart rate (Lagouge
et al., 2006), and even to lower blood pressure (Rivera et al.,
2009). Also, in human obese subjects, endothelial function and
cardiovascular health dose-dependently improved after 1 week
of resveratrol supplementation (Wong et al., 2010). Similarly,
healthy nonobese individuals also improved their cardiovascular
risk after 6months of calorie restriction, as evidenced by a reduc-
tion in blood pressure (Lefevre et al., 2009). Another indication
that general health was improved upon resveratrol treatment
was the decreased expression levels of genes of inflammatory
pathways, as were plasma levels of several inflammatory
markers and leukocyte numbers.
Our data also point toward favorable effects on glucose
homeostasis after 30 days of resveratrol supplementation in
obese subjects. Indeed, HOMA indexwas improved after resver-
atrol, suggesting favorable effects on insulin sensitivity. These
beneficial effects of resveratrol on metabolism are in concor-
dance with several findings of resveratrol supplementation in
animals (Baur et al., 2006; Canto´ et al., 2009; Lagouge et al.,
2006; Pearson et al., 2008; Sun et al., 2007). Unfortunately, we
could not determine if these effects resulted in improved
whole-body insulin sensitivity.
In conclusion, we demonstrate beneficial effects of resveratrol
supplementation for 30 days on the metabolic profile in healthy
obese males, which seems to reflect effects observed during
calorie restriction (Table S4). Although most of the effects that
we observed were modest, they were very consistently pointing
toward beneficial metabolic adaptations. Furthermore, there
were no effects on safety parameters, and no adverse events
were reported. Therefore, resVida was safe and well tolerated
at the tested concentration. Future studies should investigate
the long-term and dose-dependent metabolic effects of resver-
atrol supplementation in order to further establish whether res-
veratrol supplementation has the potential to overcome the
metabolic aberrations that are associated with obesity in
humans.EXPERIMENTAL PROCEDURES
The study protocol was reviewed and approved by the Medical Ethical
Committee of Maastricht University Medical Center (MUMC). All study partic-
ipants gave written informed consent before initiation of the study.
Subject Characteristics
Eleven healthy, obese, male volunteers without family history of diabetes or
any other endocrine disorder participated in this study (Table 1). None of the
subjects was on medication or engaged in sports activities for more than
2 hr per week. Body composition was determined by a dual-energy X-ray
absorptiometry scan (DEXA, Discovery A; Hologic, Bedford, MA), andmaximal
aerobic capacity was measured as described (Kuipers et al., 1985).Cell MClinical Study Design
Subjects participated in two experimental trials: a placebo and a resVida
(150 mg/day trans-resveratrol [99.9%; provided by DSM Nutritional Products,
Ltd.]) condition, in a randomized double-blind crossover design with a 4 week
wash-out period. Subjects were instructed to take the first supplement on the
day after baseline measurements (day 1) and the last supplement in the
evening on day 29. The subjects were instructed to abstain from alcoholic
beverages and foods containing substantial amounts of resveratrol (e.g.,
wine, red grapes, peanuts, and berries) and were advised not to take any other
food supplements during the study period. Compliance with these instructions
was confirmed by verbal declaration of the subjects. Subjects were advised to
maintain their normal living, activity, and sleeping patterns during the interven-
tion period. At the start (day 0) and end (day 30) of both intervention periods
(resveratrol and placebo), blood samples were analyzed for general safety
parameters including clinical chemistry, hematology, and coagulation values.
A 12-lead ECG (Lame´ris, Veenendaal, The Netherlands) was performed at the
beginning and end of both the resveratrol and placebo intervention. Each
experimental trial lasted 4 weeks, during which the subjects came on a weekly
basis (days 0, 7, 14, 21, and 30) to the university. The weekly checkup took
place in the morning after an overnight fast and included a measurement of
body mass and withdrawal of a small blood sample for the analysis of resver-
atrol (original and metabolites) to confirm compliance to the protocol. On day
28 in the evening, subjects came to the university for proton magnetic reso-
nance spectroscopy (1H-MRS) measurements of the liver to quantify IHL
content, and postexercise PCr recovery rate was examined by 31P-MRS to
estimate in vivo mitochondrial function (Schrauwen-Hinderling et al., 2007).
To standardize food intake, subjects had lunch with the same food items in
the two conditions and, after lunch, stayed fasted until the start of the
measurement at 17 hr.
After the MRS measurements on day 28, subjects stayed in the respiration
chamber during 36 hr to allow measurement of 24 hr substrate oxidation
and energy expenditure (Schoffelen et al., 1997). Before their stay in the respi-
ration chamber, a standardized evening meal was provided. In the respiration
chamber, subjects were fed in energy balance (2332.5 kcal/day, 13.1 g of
protein, 54.0 g of carbohydrate, 32.9 g of fat) and followed an activity protocol
as described (Schrauwen et al., 1997). In the morning of day 30, after subjects
left the respiration chamber, a muscle biopsy was taken to investigate ex vivo
mitochondrial respiration, which was followed by the withdrawal of a fasting
blood sample for the analysis of the effect of resveratrol on circulating
substrates. Hereafter, adipose tissue and skeletal muscle lipolysis was exam-
ined by means of microdialysis.
Plasma Biochemistry
To check compliance, resveratrol metabolites were measured by mass
spectrometry in plasma on days 0, 7, 14, 21, 29, and 30 as described in the
Supplemental Experimental Procedures.
In the morning of day 30, after a standardized overnight fast for 12 hr and
during the postprandial microdialysis test, blood samples were withdrawn
for the determination of plasma metabolites according to standard proce-
dures. Full experimental detail is described in the Supplemental Experimental
Procedures.
Blood Pressure
On day 0 and day 30, blood pressure was measured after an overnight fast. By
placing an automatic inflatable cuff (Omron Healthcare, Hamburg, Germany)
on the nondominant arm in the resting condition, systolic and diastolic blood
pressure was measured in triplicate. Mean systolic and diastolic blood pres-
sure values were used to calculate the mean arterial pressure.
Lipid Accumulation in Liver
On day 28, before subjects underwent the respiration chamber measurement,
1H-MRS was used to quantify IHL on a 3T whole-body scanner (Achieva, Phi-
lips Healthcare, Best, The Netherlands) using a five-element coil as described
(Hamilton et al., 2011), but with a repetition time of 4000 ms, echo time of
37 ms, and number of averages of 64. To minimize motion artifacts, subjects
were asked to breathe in the rhythm of the measurement and to be at end-
expiration during acquisition of spectra. To determine the intensity of the lipid
peak, the water signal was suppressed using frequency-selective prepulses.etabolism 14, 612–622, November 2, 2011 ª2011 Elsevier Inc. 619
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averages = 32), and spectra were fitted with AMARES (Vanhamme et al., 1997)
in the jMURI software (Naressi et al., 2001). Values are given as T2-corrected
ratios (according to Hamilton et al., 2011) of the CH2 peak, relative to the
unsuppressed water resonance (as percentage).
31P-MRS-Based Measurement of Mitochondrial Function
On day 28, 31P-MRSmeasurements were performed in vastus lateralis muscle
on a 1.5T whole-body scanner (Intera, Philips Health Care, Best, The Nether-
lands) essentially according to an established methodology (Schrauwen-Hin-
derling et al., 2007).
Muscle Biopsy
On day 30, when subjects left the respiration chamber, a muscle biopsy was
taken from the vastus lateralis muscle under local anesthesia (2% lidocaine),
as previously described (Phielix et al., 2008). A portion of the muscle tissue
was directly frozen in melting isopentane and stored at 80C until assayed.
Another portion (30 mg) was immediately placed in ice-cold preservation
medium for determination of ex vivo mitochondrial respiration (Phielix et al.,
2008).
Molecular and Protein Expression
Mitochondrial DNA copy number, gene expression by microarray, and protein
expression by western blot were performed according to standard procedures
as described in the Supplemental Experimental Procedures.
High-Resolution Respirometry
Permeabilized muscle fibers were immediately prepared from the muscle
tissue collected in the preservation medium, as described elsewhere (Boushel
et al., 2007; Phielix et al., 2008). Subsequently, the permeabilizedmuscle fibers
(2.5 mg wet weight) were analyzed for mitochondrial function using an
oxygraph (OROBOROS Instruments, Innsbruck, Austria) (Hoeks et al., 2010).
Intramyocellular Lipids
Fresh cryosections (5 mm) were stained for IMCLs by oil red O staining
combined with fibertyping and immunolabeling of the basal membrane marker
laminin to allow quantification of IMCL, as described (Koopman et al., 2001).
Postprandial Substrate Utilization and Tissue Lipolysis
In ten subjects, the lipolytic effects of resveratrol in adipose tissue and skeletal
muscle were successfully determined by microdialysis, essentially according
to Goossens et al., 2004. A full description of the microdialysis method is
provided in the Supplemental Information.
Statistical Analysis
Kolmogorov-Smirnov normality test was performed to evaluate normality
distribution. Student’s paired t test was used to compare placebo and resVida
supplementation in normally distributed data; otherwise, Wilcoxon signed-
rank test was used. For themicrodialysis test day, postprandial AUC of plasma
and interstitial metabolites and indirect calorimetry data were calculated using
the trapezium rule. In addition to the total AUC (0–6 hr after meal ingestion), the
early (0–2 hr), mid (2–4 hr), and late (4–6 hr) AUCs were also calculated to
obtain more detailed information about the time course of postprandial
responses. A p value <0.05 was considered statistically significant. Data are
reported asmean ± SEM. Statistical analyses were performed using the statis-
tical program SPSS 16.0 for Mac OS X.
ACCESSION NUMBERS
Raw microarray data sets have been submitted to NCBI Gene Expression
Omnibus (GSE32357).
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